Cytogenetics of extramedullary manifestations in multiple myeloma
Standard
Cytogenetics of extramedullary manifestations in multiple myeloma. / Billecke, Lisa; Murga Penas, Eva M; May, Annette M; Engelhardt, Monika; Nagler, Arnon; Leiba, Merav; Schiby, Ginette; Kröger, Nicolaus; Zustin, Josef; Marx, Andreas; Matschke, Jakob; Tiemann, Markus; Goekkurt, Eray; Heidtmann, Hans-Heinrich; Vettorazzi, Eik; Dierlamm, Judith; Bokemeyer, Carsten; Schilling, Georgia.
In: BRIT J HAEMATOL, Vol. 161, No. 1, 1, 2013, p. 87-94.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cytogenetics of extramedullary manifestations in multiple myeloma
AU - Billecke, Lisa
AU - Murga Penas, Eva M
AU - May, Annette M
AU - Engelhardt, Monika
AU - Nagler, Arnon
AU - Leiba, Merav
AU - Schiby, Ginette
AU - Kröger, Nicolaus
AU - Zustin, Josef
AU - Marx, Andreas
AU - Matschke, Jakob
AU - Tiemann, Markus
AU - Goekkurt, Eray
AU - Heidtmann, Hans-Heinrich
AU - Vettorazzi, Eik
AU - Dierlamm, Judith
AU - Bokemeyer, Carsten
AU - Schilling, Georgia
N1 - © 2013 Blackwell Publishing Ltd.
PY - 2013
Y1 - 2013
N2 - Extramedullary disease in patients with multiple myeloma is a rare event, occurring mostly in advanced disease or relapse. Outcome is poor and prognostic factors predicting the development of extramedullary disease have not been defined. We investigated cytogenetic alterations of myeloma cells in different extramedullary manifestations by adapting the fluorescence in situ hybridization (FISH) technique in combination with cytoplasmic immunoglobulin staining to study the cytogenetics of plasma cell tumours on paraffin embedded material. Thirty six patients were investigated: 19 with extramedullary disease, 11 with skeletal extramedullary disease and six with solitary extramedullary plasmacytoma. The first two groups showed the following results: del(17p13) 32% vs. 27%, del(13q14) 35% vs. 27%, MYC-overrepresentation 28% vs. 18% and t(4;14) 37% vs. 18%. We detected an overall higher incidence of del(17p13) in both groups compared to data from bone marrow samples of multiple myeloma reported to date (range 7-16%). The solitary extramedullary plasmacytomas presented overall less cytogenetic aberrations than the other groups. Most important, three patients with extramedullary disease and one with skeletal extramedullary disease presented different FISH findings in the extramedullary tumour compared to their bone marrow plasma cells. del(17p13), occurring additional in three of four cases, seems a strong marker for extramedullary progression of myeloma.
AB - Extramedullary disease in patients with multiple myeloma is a rare event, occurring mostly in advanced disease or relapse. Outcome is poor and prognostic factors predicting the development of extramedullary disease have not been defined. We investigated cytogenetic alterations of myeloma cells in different extramedullary manifestations by adapting the fluorescence in situ hybridization (FISH) technique in combination with cytoplasmic immunoglobulin staining to study the cytogenetics of plasma cell tumours on paraffin embedded material. Thirty six patients were investigated: 19 with extramedullary disease, 11 with skeletal extramedullary disease and six with solitary extramedullary plasmacytoma. The first two groups showed the following results: del(17p13) 32% vs. 27%, del(13q14) 35% vs. 27%, MYC-overrepresentation 28% vs. 18% and t(4;14) 37% vs. 18%. We detected an overall higher incidence of del(17p13) in both groups compared to data from bone marrow samples of multiple myeloma reported to date (range 7-16%). The solitary extramedullary plasmacytomas presented overall less cytogenetic aberrations than the other groups. Most important, three patients with extramedullary disease and one with skeletal extramedullary disease presented different FISH findings in the extramedullary tumour compared to their bone marrow plasma cells. del(17p13), occurring additional in three of four cases, seems a strong marker for extramedullary progression of myeloma.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Retrospective Studies
KW - Chromosome Deletion
KW - In Situ Hybridization, Fluorescence
KW - Chromosome Aberrations
KW - Chromosomes, Human, Pair 17/genetics
KW - Multiple Myeloma/genetics/pathology/therapy
KW - Plasmacytoma/genetics/pathology
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Retrospective Studies
KW - Chromosome Deletion
KW - In Situ Hybridization, Fluorescence
KW - Chromosome Aberrations
KW - Chromosomes, Human, Pair 17/genetics
KW - Multiple Myeloma/genetics/pathology/therapy
KW - Plasmacytoma/genetics/pathology
U2 - 10.1111/bjh.12223
DO - 10.1111/bjh.12223
M3 - SCORING: Journal article
C2 - 23368088
VL - 161
SP - 87
EP - 94
JO - BRIT J HAEMATOL
JF - BRIT J HAEMATOL
SN - 0007-1048
IS - 1
M1 - 1
ER -